Although most men with low-risk prostate cancer are now managed initially with active surveillance, use of this approach remains suboptimal, according to investigators.
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Investigators report a 24-month recurrence-free survival rate of 82% with the use of intravesical gemcitabine/docetaxel following complete transurethral resection of bladder tumor.